Related Experiment Video
Updated: Sep 14, 2026

Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
Oral challenges to detect aspirin and sulfite sensitivity in asthma
1Department of Allergy, Scripps Clinic and Research Foundation, La Jolla, California.
Abstract:
Oral challenge with aspirin or potential cross-reacting substances (including other nonsteroidal anti-inflammatory drugs [NSAIDs] or food and drug additives) is an effective method for establishing the presence of sensitivity to these substances in asthmatic subjects. Sulfite challenges can be performed in a similar manner. However, many of these subjects have concomitant active irritable airways that could make testing both inaccurate and potentially dangerous. This paper contains strategies for dealing with these problems as well as other important details in conducting oral challenges in asthmatic subjects in a manner which will lead to valid data and conclusions.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Asthma-I: Introduction
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Sputum Studies II: Culture and Sensitivity
Sputum culture and sensitivity is a medical procedure used to diagnose bacterial infections in the respiratory tract and select the most appropriate antibiotics for treatment. This process involves analyzing sputum samples of thick and opaque secretions produced in the lungs and airways. These samples are collected from patients and then sent to the laboratory for analysis.
The test can identify various pathogens responsible for respiratory infections, including Streptococcus,...
Asthma I: Introduction
Asthma III: Clinical Manifestations

